Sifalimumab

Sifalimumab
	Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α
Clinical data
ATC code	none;
Identifiers
CAS Number	1006877-41-3 ;
ChemSpider	none;
UNII	XOY1YA7RMC;
KEGG	D09668;
Chemical and physical data
Formula	C6518H10008N1724O2032S38
Molar mass	146252.08 g·mol−1
	(what is this?) (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.[1]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[2][3][4]

References

"Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
"Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
"Sifalimumab". AdisInsight. Retrieved 31 July 2017.
"Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.

[2] "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.

[3] "Sifalimumab". AdisInsight. Retrieved 31 July 2017.

[4] "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.